FindTrial
Sign In

Conditioning Regimen

DRUG7 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Swedish Orphan Biovitrum, Tehran University of Medical Sciences, Regimmune Corporation, Assistance Publique - Hôpitaux de Paris

Conditions

Acute Myeloid Leukemia (AML)Atypical Chronic Myeloid LeukemiaChronic Myelomonocytic LeukemiaEnd-stage Renal DiseaseGraft Versus Host DiseaseGraft vs Host DiseaseHematologic MalignanciesKidney Transplantation

Phase 1

Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant
CompletedNCT00063817
National Institute of Allergy and Infectious Diseases (NIAID)End-stage Renal Disease, Kidney Transplantation, Renal Transplantation
Start: 2003-06-30End: 2009-07-31Updated: 2017-12-27
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
CompletedNCT01379209
Regimmune CorporationGraft Versus Host Disease
Start: 2011-09-30End: 2017-04-30Updated: 2019-10-23

Phase 2

Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
CompletedNCT00189488
Swedish Orphan BiovitrumGraft Versus Host Disease, Hematologic Malignancies
Start: 2005-12-31End: 2013-08-31Updated: 2014-09-15
Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis
NCT01238328
Tehran University of Medical SciencesMucopolysaccharidosis
Start: 2009-09-30End: 2012-12-31Target: 10Updated: 2012-06-04
Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT
CompletedNCT02876679
Assistance Publique - Hôpitaux de ParisGraft vs Host Disease
Start: 2017-04-06End: 2020-10-12Updated: 2020-11-20
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
WithdrawnNCT04395092
Kiadis PharmaAcute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Start: 2020-11-13End: 2023-11-30Updated: 2021-06-22
Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders
Active, not recruitingNCT04761770
Memorial Sloan Kettering Cancer CenterAtypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Overlapping Syndrome +2
Start: 2021-02-15End: 2027-02-01Updated: 2026-02-17

Related Papers

Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies
Blood2024-11-051 citations
Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.
2024-02-1916 citations
BMT CTN 1803: Haploidentical Natural Killer Cells (K-NK002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
Blood2020-11-04